VIDAZA 25 MG/ML POLVO PARA SUSPENSION INYECTABLE

( ARTG ) a)Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS) according to the International Prognostic Scoring System (IPSS), b)Chronic Myelomonocytic Leukemia (CMMoL 10%-29% marrow blasts without Myeloproliferative Disorder)), c) Acute Myeloid Leukemia (AML) with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation Classification (WHO). in whom allogenic stem cell transplantation is not indicated.